Synonyms that are in the dictionary are marked in green. Synonyms that are not in the dictionary are marked in red.
Antonyms that are in the dictionary are marked in green. Antonyms that are not in the dictionary are marked in red.
Barclays lifted their price objective on DexCom from $110.00 to $115.00 in a research note on Monday, May 1st.
Citigroup upped their price target on shares of DexCom from $117.00 to $146.00 and gave the company a “buy” rating in a research report on Monday, December 12th.
Equities analysts anticipate that DexCom, Inc. will post 1.07 earnings per share for the current year.
Fulton Bank N.A. increased its position in shares of DexCom by 3.7% during the fourth quarter.
Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of DexCom by 3,596.7% during the first quarter.
In other DexCom news, Director sold 1,000 shares of the business’s stock in a transaction dated Monday, October 16th.
Oregon Public Employees Retirement Fund’s holdings in DexCom were worth $3,883,000 as of its most recent filing with the Securities and Exchange Commission.
RMR Wealth Builders lifted its stake in shares of DexCom by 1.8% in the third quarter.
Robert W. Baird upped their price target on shares of DexCom from $97.00 to $120.00 in a research report on Friday, October 28th.
Stifel Nicolaus raised their target price on shares of DexCom from $130.00 to $140.00 in a report on Friday, April 28th.
Toronto Dominion Bank Buys 29,512 Shares of DexCom, Inc.
Source: https://www.americanbankingnews.com/2023/05/05/adient-nyseadnt-announces-earnings-results.html
Weight loss drugs do not necessarily compete with DexCom.
Wells Fargo & Company raised their price objective on shares of DexCom from $110.00 to $136.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 13th.